| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update |
| 08 Sep 2026 |
8-K: Other Events
Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance. |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation. |
| 28 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Name of entity as on file with the Nevada Secretary of State : RELMADA THERAPEUTICS, INC. Entity or Nevada Business Identification Number (NVID) : NV20121345551 1. Entity information Certificate to Accompany Restated Articles or Amended ... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a dura... |
| 20 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 9, 2026, by and among Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (e... |
| 15 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your crede... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates |
| 05 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Introductory. Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 40,142,000 shares of its common stock, pa... |
| 04 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Unlocking Life Changing Therapies October 2025 C O R PO R AT E O VER VI E W |
| 17 Sep 2025 |
8-K: Regulation FD Disclosure
Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W |
| 16 Sep 2025 |
8-K: Other Events
CORAL GABLES, FL – September 16, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous... |
| 10 Sep 2025 |
8-K: Regulation FD Disclosure
Unlocking Life Changing Therapies August 2025 C O R PO R AT E O VER VI E W |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the “Company”), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share. |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC |
| 23 Jul 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the... |
| 10 Jul 2025 |
8-K: Termination of a Material Definitive Agreement
In January 2018, Relmada Therapeutics, Inc. (“Relmada,” the “Company,” “we,” “us,” “our”) entered into a License Agreement (the “License Agreement”) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursu... |
Loading...